Form 4: Disc Medicine COO Sells Shares Under 10b5-1 Plan

Disc Medicine, Inc. Chief Operating Officer Jonathan Yen-Wen Yu executed a Rule 10b5-1 trading plan, resulting in the sale of company stock and the acquisition of stock options.

Summary

• Jonathan Yen-Wen Yu, Chief Operating Officer of Disc Medicine, Inc., engaged in stock transactions on June 16, 2026.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on March 17, 2026.
• Yu acquired 5,261 shares of common stock at $9.86 per share and an additional 13,351 shares at the same price.
• Concurrently, Yu disposed of 11,651 shares at a weighted average price of $68.7582 and 6,961 shares at a weighted average price of $69.918.
• Following these transactions, Yu beneficially owns 61,285 shares from the sales and 54,324 shares from the sales.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the sale of shares by an executive can be a negative signal, the execution under a Rule 10b5-1 plan mitigates concerns about insider trading and suggests a pre-determined strategy.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider trading activity.
• Yu acquired stock options, suggesting continued commitment or incentive alignment with the company's performance.
• The acquisition of stock options is for 5,261 shares and 13,351 shares, with the underlying shares fully vested and exercisable.

Negatives

• A significant number of shares were sold by a key executive, which could be perceived negatively by the market.
• The sales occurred at prices significantly higher than the acquisition price of the newly acquired shares, indicating a realization of gains.

Risks

• The sale of a substantial number of shares by a high-ranking executive could signal a lack of confidence in future stock price appreciation, although executed under a 10b5-1 plan.
• The weighted average sale prices indicate that the executive is realizing gains from previous stock appreciation.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

Industry Context

StockSavvy.ai notes that the use of Rule 10b5-1 plans is a common and accepted practice for corporate insiders to diversify their holdings or manage personal finances without creating the appearance of trading on material non-public information. However, significant sales by executives can still influence market perception.

Stakeholder Impact

• Shareholders: May interpret the executive's stock sales as a potential negative signal, despite the Rule 10b5-1 plan, potentially leading to short-term price pressure.
• Employees: May observe the executive's actions as a benchmark for their own stock holdings and potential sales.
• Management: The executive's actions are within established compliance frameworks.

Next Steps

• The reporting person may continue to execute transactions under the Rule 10b5-1 plan.
• The company may be required to provide further details on specific sale prices upon request from the SEC or security holders.

Key Dates

Keywords

Form 4, Insider Trading, Rule 10b5-1, Disc Medicine, Jonathan Yen-Wen Yu, Stock Options, Beneficial Ownership, Common Stock, SEC Filing